Current Research Therapeutic Strategies for Alzheimer’s Disease Treatment

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics

Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864 · see citing works

Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy

Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359 · see citing works

Alzheimer's disease: the amyloid cascade hypothesis

Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · see citing works

Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures

Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,970 · see citing works

2016 Alzheimer's disease facts and figures

Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069 · see citing works

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · see citing works

Alzheimer Mechanisms and Therapeutic Strategies

Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758 · see citing works

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · see citing works

2015 Alzheimer's disease facts and figures

Alzheimer's Association (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.02.003 · Cited by 1,641 · see citing works

Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329 · see citing works

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224 · see citing works

The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease

Spires-Jones, T. L., & Hyman, B. T. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.004 · Cited by 1,201 · see citing works

Trafficking and Proteolytic Processing of APP

Haass, C., Kaether, C., Thinakaran, G., & Sisodia, S. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006270 · Cited by 1,075 · see citing works

Neurotoxicity of Amyloid  -Protein: Synaptic and Network Dysfunction

Mucke, L., & Selkoe, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006338 · Cited by 1,000 · see citing works

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease

Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686 · see citing works

DT‐01‐04: The efficacy of RVT‐101, a 5‐ht6 receptor antagonist, as an adjunct to donepezil in adults with mild‐to‐moderate Alzheimer's disease: Completer analysis of a phase 2b study

Lombardo, I., Ramaswamy, G., Piscitelli, S. C., & Friedhoff, L. T. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.08.154 · Cited by 656 · see citing works

Inflammation, Defective Insulin Signaling, and Mitochondrial Dysfunction as Common Molecular Denominators Connecting Type 2 Diabetes to Alzheimer Disease

Felice, F. G. D., & Ferreira, S. T. (2014) · Diabetes · doi:10.2337/db13-1954 · Cited by 647 · see citing works

NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo

Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18162 · Cited by 634 · see citing works

Targeting the β secretase BACE1 for Alzheimer’s disease therapy

Yan, R., & Vassar, R. (2014) · Lancet Neurology · doi:10.1016/s1474-4422(13)70276-x · Cited by 550 · see citing works

A Phase II Trial of Tideglusib in Alzheimer's Disease

Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141959 · Cited by 536 · see citing works

Identifying and validating biomarkers for Alzheimer's disease

Humpel, C. (2011) · Trends in Biotechnology · doi:10.1016/j.tibtech.2010.09.007 · Cited by 484 · see citing works

Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence

Freiherr, J., Hallschmid, M., Frey, W. H., Brünner, Y. F., Chapman, C. D., Hölscher, C., Craft, S., Felice, F. G. D., & Benedict, C. (2013) · CNS Drugs · doi:10.1007/s40263-013-0076-8 · Cited by 470 · see citing works

Long-Acting Intranasal Insulin Detemir Improves Cognition for Adults with Mild Cognitive Impairment or Early-Stage Alzheimer's Disease Dementia

Claxton, A., Baker, L. D., Hanson, A., Trittschuh, E. H., Cholerton, B., Morgan, A., Callaghan, M., Arbuckle, M., Behl, C., & Craft, S. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141791 · Cited by 467 · see citing works

Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β

Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W. F., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110977 · Cited by 448 · cited 1× · see citing works

TNF-α Mediates PKR-Dependent Memory Impairment and Brain IRS-1 Inhibition Induced by Alzheimer’s β-Amyloid Oligomers in Mice and Monkeys

Lourenco, M. V., Clarke, J. R., Frozza, R. L., Bomfim, T. R., Forny‐Germano, L., Batista, A. F., Sathler, L. B., Brito‐Moreira, J., Amaral, O. B., Silva, C. A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.11.002 · Cited by 415 · see citing works

The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice

Zhang, B., Carroll, J., Trojanowski, J. Q., Yao, Y., Iba, M., Potuzak, J. S., Hogan, A.-M. L., Xie, S. X., Ballatore, C., Smith, A. B., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4922-11.2012 · Cited by 401 · see citing works

Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease

Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H., & Iwamoto, T. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.10.009 · Cited by 387 · see citing works

PGC-1α Expression Decreases in the Alzheimer Disease Brain as a Function of Dementia

Qin, W., Haroutunian, V. H., Katsel, P., Cardozo, C. P., Ho, L., Buxbaum, J. D., & Pasinetti, G. M. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.588 · Cited by 381 · see citing works

Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease

Coric, V., van Dyck, C. H., Salloway, S., Andreasen, N., Brody, M., RICHTER, R. W., Soininen, H. S., Thein, S., Shiovitz, T. M., Pilcher, G. D., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.2194 · Cited by 374 · see citing works

Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study

Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361 · see citing works

Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease

Ferreira, S. T., Clarke, J. R., Bomfim, T. R., & Felice, F. G. D. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.12.010 · Cited by 354 · see citing works

Dietary and lifestyle guidelines for the prevention of Alzheimer's disease

Barnard, N. D., Bush, A. I., Ceccarelli, A., Cooper, J. K., de Jager, C. A., Erickson, K. I., Fraser, G. E., Kesler, S. R., Levin, S., Lucey, B. P., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.033 · Cited by 340 · see citing works

Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease

Baranello, R., Bharani, K., Padmaraju, V., Chopra, N., Lahiri, D., Greig, N., Pappolla, M., & Sambamurti, K. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666141218140953 · Cited by 331 · see citing works

Alzheimer’s disease and insulin resistance: translating basic science into clinical applications

Felice, F. G. D. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64595 · Cited by 328 · see citing works

Altered Expression of Diabetes-Related Genes in Alzheimer's Disease Brains: The Hisayama Study

Hokama, M., Oka, S., Leon, J., Ninomiya, T., Honda, H., Sasaki, K., Iwaki, T., Ohara, T., Sasaki, T., LaFerla, F. M., et al. (2013) · Cerebral Cortex · doi:10.1093/cercor/bht101 · Cited by 319 · see citing works

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease

Relkin, N. R., Szabo, P., Adamiak, B., Burgut, T., Monthé, C., Lent, R. W., Younkin, S. G., Younkin, L. H., Schiff, R. I., & Weksler, M. E. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.021 · Cited by 305 · see citing works

Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease

Jaturapatporn, D., Isaac, M. G. E. K. N., McCleery, J. M., & Tabet, N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006378.pub2 · Cited by 299 · see citing works

Physiological and pathological phosphorylation of tau by Cdk5

Kimura, T., Ishiguro, K., & Hisanaga, S. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00065 · Cited by 297 · see citing works

Tramiprosate in mild-to-moderate Alzheimer's disease — a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)

Aisen, P. S., Gauthier, S., Ferris, S. H., Saumier, D., Haine, D., Garceau, D., Duong, A., Suhy, J., Oh, J., Lau, W. C., et al. (2011) · Archives of Medical Science · doi:10.5114/aoms.2011.20612 · Cited by 295 · see citing works

Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease

Tuszynski, M. H., Yang, J. H., Barba, D., U, H.-S., Bakay, R. A. E., Pay, M. M., Masliah, E., Conner, J. M., Kobalka, P., Roy, S., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1807 · Cited by 287 · see citing works

Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer’s disease models

van Eersel, J., Ke, Y. D., Liu, X., Delerue, F., Kril, J. J., Götz, J., & Ittner, L. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009038107 · Cited by 284 · see citing works

Immunotherapeutic Approaches for Alzheimer’s Disease

Wisniewski, T., & Goñi, F. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.064 · Cited by 284 · see citing works

Tau Aggregation Inhibitor Therapy: An Exploratory Phase 2 Study in Mild or Moderate Alzheimer's Disease

Wischik, C. M., Staff, R. T., Wischik, D. J., Bentham, P., Murray, A. D., Storey, J. M. D., Kook, K. A., & Harrington, C. R. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142874 · Cited by 269 · see citing works

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182309fa5 · Cited by 258 · cited 1× · see citing works

First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model

Kontseková, E., Žilka, N., Kováčech, B., Novák, P., & Novák, M. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt278 · Cited by 248 · see citing works

Clearance mechanisms of Alzheimer's amyloid-β peptide: implications for therapeutic design and diagnostic tests

Bates, K. A., Verdile, G., Li, Q.-X., Ames, D., Hudson, P., Masters, C. L., & Martins, R. N. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.96 · Cited by 247 · see citing works

JNK3 Perpetuates Metabolic Stress Induced by Aβ Peptides

Yoon, S. O., Park, D. J., Ryu, J. C., Özer, H. G., Tep, C., Shin, Y. J., Lim, T. H., Pastorino, L., Kunwar, A. J., Walton, J. C., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.06.024 · Cited by 236 · see citing works

The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease

Drachman, D. A. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.11.003 · Cited by 224 · see citing works

Are tau aggregates toxic or protective in tauopathies?

Cowan, C. M., & Mudher, A. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00114 · Cited by 215 · see citing works

Alzheimer‐associated Aβ oligomers impact the central nervous system to induce peripheral metabolic deregulation

Clarke, J. R., Lyra e Silva, N. M., Figueiredo, C. P., Frozza, R. L., Ledo, J. H., Beckman, D., Katashima, C. K., Razolli, D., Carvalho, B. M., Frazão, R., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404183 · Cited by 214 · see citing works

Regulation of Copper and Iron Homeostasis by Metal Chelators: A Possible Chemotherapy for Alzheimer’s Disease

Robert, A., Liu, Y., Nguyen, M., & Meunier, B. (2015) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5b00119 · Cited by 212 · see citing works

The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans

May, P. C., Willis, B. A., Lowe, S. L., Dean, R. A., Monk, S. A., Cocke, P. J., Audia, J. E., Boggs, L. N., Borders, A. R., Brier, R. A., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.4129-14.2015 · Cited by 206 · see citing works

A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze

Woolley, M. L., Bentley, J., Sleight, A. J., Marsden, C. A., & Fone, K. C. F. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00056-9 · Cited by 206 · see citing works

Fyn kinase inhibition as a novel therapy for Alzheimer’s disease

Nygaard, H. B., van Dyck, C. H., & Strittmatter, S. M. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt238 · Cited by 201 · see citing works

Non-Steroidal Anti-Inflammatory Drugs as a Treatment for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Treatment Effect

Miguel-Álvarez, M., Santos‐Lozano, A., Sanchis‐Gomar, F., Fiuza‐Luces, C., Pareja-Galeano, H., Garatachea, N., & Lucía, A. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0239-z · Cited by 197 · see citing works

γ-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes

Imbimbo, B. P., & Giardina, G. A. M. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611795860942 · Cited by 195 · see citing works

The Second-Generation Active A Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects

Wießner, C., Wiederhold, K., Tissot, A. C., Frey, P., Danner, S., Jacobson, L. H., Jennings, G. T., Lüönd, R. M., Ortmann, R., Reichwald, J., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.0293-11.2011 · Cited by 190 · see citing works

Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease

Galasko, D. R., Bell, J. S., Mancuso, J. Y., Kupiec, J. W., Sabbagh, M. N., van Dyck, C. H., Thomas, R. G., Aisen, P. S. S., & Study, F. T. A. D. C. (2014) · Neurology · doi:10.1212/wnl.0000000000000364 · Cited by 187 · see citing works

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

Dodel, R. C., Rominger, A., Bartenstein, P., Barkhof, F., Blennow, K., Förster, S., Winter, Y., Bach, J., Popp, J., Alferink, J., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70014-0 · Cited by 187 · see citing works

Deregulated Cdk5 activity is involved in inducing Alzheimer's disease

Shukla, V., Skuntz, S., & Pant, H. C. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.10.015 · Cited by 185 · see citing works

The Role of the Cell Surface LRP and Soluble LRP in Blood-Brain Barrier Aβ Clearance in Alzheimers Disease

Deane, R., Sagare, A. P., & Zloković, B. V. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208784705487 · Cited by 184 · see citing works

Astrocyte physiopathology: At the crossroads of intercellular networking, inflammation and cell death

Rossi, D. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.04.003 · Cited by 178 · see citing works

Amyloid-Degrading Enzymes as Therapeutic Targets in Alzheimers Disease

Nalivaeva, N. N., Fisk, L., Belyaev, N. N., & Turner, A. J. (2008) · Current Alzheimer Research · doi:10.2174/156720508783954785 · Cited by 177 · see citing works

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial

Piette, F., Belmin, J., Vincent, H., Schmidt, N., Pariel, S., Verny, M., Marquis, C., Mely, J., Hugonot-Diener, L., Kinet, J., et al. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt75 · Cited by 176 · see citing works

Proteoglycan-mediated Inhibition of Aβ Proteolysis

Gupta‐Bansal, R., Frederickson, R. C. A., & Brunden, K. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.31.18666 · Cited by 176 · see citing works

Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice

Muhs, A., Hickman, D. T., Pihlgren, M., Chuard, N., Giriens, V., Meerschman, C., der Auwera, I. V., LEUVEN, F. V., Sugawara, M., Weingertner, M.-C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703137104 · Cited by 176 · see citing works

A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer’s disease

Pasqualetti, P., Bonomini, C., Dal Forno, G., Paulon, L., Sinforiani, E., Marra, C., Zanetti, O., & Maria Rossini, P. (2009) · Aging Clinical and Experimental Research · doi:10.1007/bf03325217 · Cited by 172 · see citing works

Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer’s disease model

Corcoran, N. M., Martin, D., Hutter‐Paier, B., Windisch, M., Nguyen, T. T., Nheu, L., Sundström, L., Costello, A. J., & Hovens, C. M. (2010) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2010.04.020 · Cited by 168 · see citing works

Clioquinol promotes the degradation of metal-dependent amyloid-β (Aβ) oligomers to restore endocytosis and ameliorate Aβ toxicity

Matlack, K. E. S., Tardiff, D. F., Narayan, P. S., Hamamichi, S., Caldwell, K. A., Caldwell, G. A., & Lindquist, S. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402228111 · Cited by 166 · see citing works

Safety and efficacy of idalopirdine, a 5-HT 6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial

Wilkinson, D. G., Windfeld, K., & Colding‐Jørgensen, E. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70198-x · Cited by 164 · see citing works

Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimers Disease Treatment

Weinreb, O., Amit, T., Bar‐Am, O., & Youdim, M. B. H. (2012) · Current Drug Targets · doi:10.2174/138945012799499794 · Cited by 154 · see citing works

Antibody-targeted drugs and drug resistance—Challenges and solutions

Shefet-Carasso, L., & Benhar, I. (2014) · Drug Resistance Updates · doi:10.1016/j.drup.2014.11.001 · Cited by 150 · see citing works

Post-mortem analysis of neuroinflammatory changes in human Alzheimer’s disease

Gomez-Nicola, D., & Boche, D. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0126-1 · Cited by 147 · see citing works

A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?

Francis, P. T., Nordberg, A. K., & Arnold, S. E. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.12.010 · Cited by 140 · see citing works

β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer’s disease

Menting, K. W., & Claassen, J. A. H. R. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00165 · Cited by 139 · see citing works

Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau

Hochgräfe, K., Sydow, A., Matenia, D., Cadinu, D., Könen, S., Petrova, O. M., Pickhardt, M., Goll, P., Morellini, F., Mandelkow�, E., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0204-4 · Cited by 137 · see citing works

The protein tyrosine kinase, fyn, in Alzheimerʼs disease pathology

Shirazi, S. K., & Wood, J. G. (1993) · Neuroreport · doi:10.1097/00001756-199304000-00024 · Cited by 136 · see citing works

Effect of tramiprosate in patients with mild-to-moderate alzheimer's disease: Exploratory analyses of the MRI sub-group of the alphase study

Gauthier, S. G., Aisen, P. S. S., Ferris, S. H., Saumier, D., Duong, A., Haine, D., Garceau, D., Suhy, J., Oh, J., Lau, W. C., et al. (2009) · The journal of nutrition health & aging · doi:10.1007/s12603-009-0106-x · Cited by 136 · see citing works

NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo

Eriksen, J. L., Sagi, S. A., Smith, T. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318162 · Cited by 135 · see citing works

Importance of the nicotinic acetylcholine receptor system in the prefrontal cortex

Wallace, T. L., & Bertrand, D. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.04.001 · Cited by 133 · see citing works

Cholinergic System Dysfunction and Neurodegenerative Diseases: Cause or Effect?

Tata, A. M., Velluto, L., D’Angelo, C., & Reale, M. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140917121132 · Cited by 132 · see citing works

Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition

Adler, B. L., Yarchoan, M. M., Hwang, H. M., Louneva, N., Blair, J. A., Palm, R. F., Smith, M. A., Lee, H., Arnold, S. E., & Casadesús, G. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.10.076 · Cited by 131 · see citing works

The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease

Vassar, R. J., & Kandalepas, P. C. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt82 · Cited by 130 · see citing works

Targeting JNK3 for the treatment of neurodegenerative disorders

Resnick, L., & Fennell, M. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03251-9 · Cited by 128 · see citing works

Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer’s Disease

Baddeley, T. C., McCaffrey, J., Storey, J. M. D., Cheung, J. K. S., Melis, V., Horsley, D., Harrington, C. R., & Wischik, C. M. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.219352 · Cited by 128 · see citing works

PPARγ Co-Activator-1α (PGC-1α) Reduces Amyloid-β Generation Through a PPARγ-Dependent Mechanism

Katsouri, L., Parr, C., Bogdanović, N., Willem, M., & Sastre, M. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101356 · Cited by 126 · see citing works

The French Series of Autosomal Dominant Early Onset Alzheimer's Disease Cases: Mutation Spectrum and Cerebrospinal Fluid Biomarkers

Wallon, D., The collaborators of the GMAJ project, Rousseau, S., Rovelet‐Lecrux, A., Quillard‐Muraine, M., Guyant‐Maréchal, L., Martinaud, O., Pariente, J., Puel, M., Rollin‐Sillaire, A., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120172 · Cited by 124 · see citing works

The Role of CDK5/P25 Formation/Inhibition in Neurodegeneration

Camins, A., Verdaguer, E., Folch, J., Canudas, A. M., & Pallàs, M. (2006) · Drug News & Perspectives · doi:10.1358/dnp.2006.19.8.1043961 · Cited by 124 · see citing works

Brain metabolic stress and neuroinflammation at the basis of cognitive impairment in Alzheimer’s disease

Felice, F. G. D., & Lourenco, M. V. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00094 · Cited by 120 · see citing works

Bapineuzumab and solanezumab for Alzheimer's disease: is the ‘amyloid cascade hypothesis’ still alive?

Tayeb, H. O., Murray, E. D., Price, B. H., & Tarazi, F. I. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.789856 · Cited by 119 · see citing works

Colostrinin1 (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease

Bilikiewicz, A., & Gaus, W. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6103 · Cited by 117 · see citing works

Design, Synthesis, and Evaluation of Multitarget-Directed Selenium-Containing Clioquinol Derivatives for the Treatment of Alzheimer’s Disease

Wang, Z., Wang, Y., Li, W., Mao, F., Sun, Y., Huang, L., & Li, X. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500119g · Cited by 116 · see citing works

The dendritic hypothesis for Alzheimer's disease pathophysiology

Cochran, J. N., Hall, A. M., & Roberson, E. D. (2014) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2013.12.004 · Cited by 114 · see citing works

Association of Alzheimer disease pathology with abnormal lipid metabolism

Matsuzaki, T., Sasaki, K., Hata, J., Hirakawa, Y., Fujimi, K., Ninomiya, T., Suzuki, S. O., Kanba, S., Kiyohara, Y., & Iwaki, T. (2011) · Neurology · doi:10.1212/wnl.0b013e31822e145d · Cited by 108 · see citing works

Inhibition of c‐ J un N ‐terminal kinase activation reverses A lzheimer disease phenotypes in APP swe/ PS 1dE 9 mice

Zhou, Q., Wang, M., Du, Y., Zhang, W., Bai, M., Zhang, Z., Li, Z., & Miao, J. (2015) · Annals of Neurology · doi:10.1002/ana.24361 · Cited by 105 · see citing works

Can Nutrients Prevent or Delay Onset of Alzheimer's Disease?

Kamphuis, P. J. G. H., & Scheltens, P. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091558 · Cited by 100 · see citing works

Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward

Panza, F., Solfrizzi, V., Imbimbo, B. P., Tortelli, R., Santamato, A., & Logroscino, G. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.883921 · Cited by 97 · see citing works

On the origin of Alzheimer's disease. Trials and tribulations of the amyloid hypothesis

Castello, M. A., & Soriano, S. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.10.001 · Cited by 95 · see citing works

Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline

Gourmaud, S., Paquet, C., Dumurgier, J., Pace, C., Bouras, C., Gray, F., Laplanche, J., MEURS, E. F., Mouton‐Liger, F., & Hugon, J. (2015) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.140062 · Cited by 95 · see citing works

Is RAGE Still A Therapeutic Target For Alzheimer’s Disease?

Deane, R. J. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.51 · Cited by 94 · see citing works

Combined Treatment with a BACE Inhibitor and Anti-Aβ Antibody Gantenerumab Enhances Amyloid Reduction in APPLondon Mice

Jacobsen, H., Ozmen, L., Caruso, A., Narquizian, R., Hilpert, H., Jacobsen, B., Terwel, D., An, T.-H., & Bohrmann, B. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1405-14.2014 · Cited by 93 · see citing works

Serotonergic Therapies for Cognitive Symptoms in Alzheimer’s Disease: Rationale and Current Status

Ramírez, M. J., Lai, M. K. P., Tordera, R. M., & Francis, P. T. (2014) · Drugs · doi:10.1007/s40265-014-0217-5 · Cited by 92 · see citing works

Nutritional approaches in the risk reduction and management of Alzheimer's disease

Mi, W., van Wijk, N., Cansev, M., Sijben, J., & Kamphuis, P. J. G. H. (2013) · Nutrition · doi:10.1016/j.nut.2013.01.024 · Cited by 88 · see citing works

Emerging Therapeutics for Alzheimer's Disease

Chiang, K., & Koo, E. H. (2014) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135932 · Cited by 88 · see citing works

γ-Secretase as a Target for Alzheimer’s Disease

Wolfe, M. S. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00004-0 · Cited by 83 · see citing works

Masitinib for the treatment of mild to moderate Alzheimer’s disease

Folch, J., Petrov, D., Ettcheto, M., Pedrós, I., Abad, S., Beas-Zarate, C., Lazarowski, A., Marin, M., Olloquequi, J., Auladell, C., et al. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1045419 · Cited by 80 · see citing works

CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo- Controlled Study

Ross, J., Sharma, S., Winston, J., Nunez, M., Bottini, G., Franceschi, M., Scarpini, E. A., Frigerio, E., Fiorentini, F., Fernández, M., et al. (2013) · Current Alzheimer Research · doi:10.2174/13892037113149990144 · Cited by 78 · see citing works

Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease

Iqbal, K., Gong, C., & Liu, F. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.870156 · Cited by 76 · see citing works

Amyloid-directed monoclonal antibodies for the treatment of Alzheimer’s disease: the point of no return?

Panza, F., Solfrizzi, V., Imbimbo, B. P., & Logroscino, G. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.935332 · Cited by 75 · see citing works

Epidemiologia da Demência e da Doença de Alzheimer em Portugal: Estimativas da Prevalência e dos Encargos Financeiros com a Medicação

Santana, I. J., Farinha, F., Freitas, S., Rodrigues, V., & Carvalho, Á. D. (2015) · Acta Médica Portuguesa · doi:10.20344/amp.6025 · Cited by 72 · see citing works

Understanding molecular mechanisms of proteolysis in Alzheimer's disease: Progress toward therapeutic interventions

Higuchi, M., Iwata, N., & Saido, T. C. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.02.013 · Cited by 72 · see citing works

Stabilization of Nontoxic Aβ-Oligomers: Insights into the Mechanism of Action of Hydroxyquinolines in Alzheimer's Disease

Ryan, T. M., Roberts, B. R., McColl, G., Hare, D. J., Doble, P., Li, Q., Lind, M., Roberts, A. M., Mertens, H. D. T., Kirby, N. M., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.2912-14.2015 · Cited by 72 · see citing works

Neuronal stress signaling and eIF2α phosphorylation as molecular links between Alzheimer's disease and diabetes

Lourenco, M. V., Ferreira, S. T., & Felice, F. G. D. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.03.003 · Cited by 71 · see citing works

Investigational drugs in Alzheimer's disease: current progress

Berk, C., Paul, G., & Sabbagh, M. N. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.905542 · Cited by 69 · see citing works

Fyn, a Potential Target for Alzheimer's Disease

Yang, K., Belrose, J. C., Trepanier, C. H., Lei, G., Jackson, M. F., & MacDonald, J. F. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110353 · Cited by 66 · see citing works

Importance and management of micronutrient deficiencies in patients with Alzheimer’s disease

Cardoso, B. R., Cominetti, & Cozzolino, S. M. F. (2013) · Clinical Interventions in Aging · doi:10.2147/cia.s27983 · Cited by 62 · see citing works

Rescue of neurons from undergoing hallmark tau-induced Alzheimer's disease cell pathologies by the antimitotic drug paclitaxel

Shemesh, O. A., & Spira, M. E. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.03.008 · Cited by 62 · see citing works

Protection against the synaptic targeting and toxicity of Alzheimer's‐associated Aβ oligomers by insulin mimetic chiro‐inositols

Pitt, J. E., Thorner, M. O., Brautigan, D. L., Larner, J., & Klein, W. L. (2012) · The FASEB Journal · doi:10.1096/fj.12-211896 · Cited by 57 · see citing works

Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease?

Qiu, W. Q., & Zhu, H. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00186 · Cited by 55 · see citing works

A novel anti-Alzheimer's disease drug, ladostigil

Weinreb, O., Amit, T., Bar‐Am, O., & Youdim, M. B. H. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-386467-3.00010-8 · Cited by 52 · see citing works

Alzheimer disease immunotherapeutics: Then and now

Jindal, H., Bhatt, B., Shashikantha, S. K., & Malik, J. S. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/21645515.2014.970959 · Cited by 52 · see citing works

Effects of Long-Term Pioglitazone Treatment on Peripheral and Central Markers of Aging

Blalock, E. M., Phelps, J. T., Pancani, T., Searcy, J. L., Anderson, K. L., Gant, J. C., Popović, J., Avdiushko, M. G., Cohen, D. A., Chen, K.-C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010405 · Cited by 51 · see citing works

MER5101, a Novel Aβ1-15:DT Conjugate Vaccine, Generates a Robust Anti-Aβ Antibody Response and Attenuates Aβ Pathology and Cognitive Deficits in APPswe/PS1ΔE9 Transgenic Mice

Liu, B., Frost, J. L., Sun, J., Fu, H., Grimes, S., Blackburn, P., & Lemere, C. A. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5924-12.2013 · Cited by 50 · see citing works

Emerging drug targets for A β and tau in Alzheimer's disease: a systematic review

West, S., & Bhugra, P. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12621 · Cited by 50 · see citing works

Measurement of anti-beta amyloid antibodies in human blood

Szabo, P., Mujalli, D. M., Rotondi, M. L., Sharma, R., Weber, A., Schwarz, H., Weksler, M. E., & Relkin, N. R. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.06.010 · Cited by 49 · see citing works

A Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Avagacestat (BMS-708163) in Healthy Young and Elderly Subjects

Dockens, R. C., Wang, J.-S., Castaneda, L., Sverdlov, O., Huang, S., Slemmon, R., Gu, H., Wong, O. T., Li, H., Berman, R., et al. (2012) · Clinical Pharmacokinetics · doi:10.1007/s40262-012-0005-x · Cited by 47 · see citing works

Profile of gantenerumab and its potential in the treatment of Alzheimer's disease

Nisticò, R., Novakovic, D., Feligioni, M., Scaccianoce, S., Piccinin, S., Mercuri, N. B., Nicoletti, F., Caruso, A., Schepisi, C., & Errico, F. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s53401 · Cited by 45 · see citing works

Rational heterodoxy: Cholesterol reformation of the amyloid doctrine

Castello, M. A., & Soriano, S. (2012) · Ageing Research Reviews · doi:10.1016/j.arr.2012.06.007 · Cited by 44 · see citing works

Neuroprotective action of flavopiridol, a cyclin-dependent kinase inhibitor, in colchicine-induced apoptosis

Jordà, E. G., Verdaguer, E., Canudas, A. M., Jiménez, A., Bruna, A., Caelles, C., Bravo, R., Escubedo, E., Pubill, D., Camarasa, J., et al. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00204-1 · Cited by 43 · see citing works

Drug Access to the Central Nervous System in Alzheimer’s Disease: Preclinical and Clinical Insights

Mehta, D. C., Short, J., Hilmer, S., & Nicolazzo, J. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1522-0 · Cited by 41 · see citing works

Invited review: Drug development for tauopathies

Grüninger, F. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12192 · Cited by 40 · see citing works

Pharmacokinetics and Pharmacodynamics of CHF5074 After Short-term Administration in Healthy Subjects

Imbimbo, B. P., Frigerio, E., Breda, M., Fiorentini, F., Fernández, M., Sivilia, S., Giardino, L., Calzà, L., Norris, D., Casula, D., et al. (2012) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3182622ace · Cited by 37 · see citing works

Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer's disease due to a novel PSEN1 mutation

Ringman, J. M., Gylys, K. H., Medina, L. D., Fox, M., Kepe, V., Flores, D. L., Apostolova, L. G., Barrio, J. R., Small, G., Silverman, D. H. S., et al. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.10.039 · Cited by 34 · see citing works

Effects of Single Doses of Avagacestat (BMS-708163) on Cerebrospinal Fluid Aβ Levels in Healthy Young Men

Tong, G., Castaneda, L., Wang, J.-S., Sverdlov, O., Huang, S., Slemmon, R., Gu, H., Wong, O. T., Li, H., Berman, R., et al. (2012) · Clinical Drug Investigation · doi:10.1007/s40261-012-0006-4 · Cited by 33 · see citing works

GSK3β inhibition is involved in the neuroprotective effects of cyclin-dependent kinase inhibitors in neurons

de la Torre, A. V., Junyent, F., Folch, J., Pelegrı́, C., Vilaplana, J., Auladell, C., Beas‐Zárate, C., Pallàs, M., Verdaguer, E., & Camins, A. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.08.006 · Cited by 27 · see citing works

Nutrition and the brain: what advice should we give?

Cooper, J. K. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.02.029 · Cited by 24 · see citing works

CHF5074 Protects SH-SY5Y Human Neuronal-like Cells from Amyloidbeta 25-35 and Tumor Necrosis Factor Related Apoptosis Inducing Ligand Toxicity In Vitro

Ronsisvalle, N., Benedetto, G. D., Parenti, C., et al. (2014) · Current Alzheimer Research · doi:10.2174/1567205011666140618104430 · Cited by 20 · see citing works

Hypothesis of Endogenous Anticholinergic Activity in Alzheimer's Disease

Konishi, K., Hori, K., Tani, M., et al. (2015) · Neurodegenerative Diseases · doi:10.1159/000381511 · Cited by 19 · see citing works

Connecting Type 2 diabetes to Alzheimer’s disease

Felice, F. G. D. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.864824 · Cited by 17 · see citing works

The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade

Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870 · see citing works

Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs

Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630 · see citing works

Natural Compounds for Alzheimer’s Disease Therapy: A Systematic Review of Preclinical and Clinical Studies

Andrade, S., Ramalho, M. J., Loureiro, J. A., & Pereira, M. D. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092313 · Cited by 240 · see citing works

Insulin-Degrading Enzyme in the Fight against Alzheimer's Disease

Kurochkin, I. V., Guarnera, E., & Berezovsky, I. N. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.10.008 · Cited by 185 · see citing works

Ketogenic Medium Chain Triglycerides Increase Brain Energy Metabolism in Alzheimer’s Disease

Croteau, E., Castellano, C.-A., Richard, M. A., Fortier, M., Nugent, S., Lepage, M., Duchesne, S., Whittingstall, K., Turcotte, É. E., Bocti, C., et al. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180202 · Cited by 135 · see citing works

Drug development for alzheimer’s disease: Microglia induced neuroinflammation as a target

Dong, Y., Li, X., Cheng, J., & Hou, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030558 · Cited by 136 · see citing works

Assessing the Preparedness of the U.S. Health Care System Infrastructure for an Alzheimer's Treatment

Liu, J., Hlavka, J., Hillestad, R., & Mattke, S. (2017) · doi:10.7249/rr2272 · Cited by 98 · see citing works

Hybrid Multifunctional Modulators Inhibit Multifaceted Aβ Toxicity and Prevent Mitochondrial Damage

Rajasekhar, K., Mehta, K., & Govindaraju, T. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00033 · Cited by 69 · see citing works

A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease

Maciejewska, K., Czarnecka, K., & Szymański, P. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00293-5 · Cited by 64 · see citing works

Tau-targeting therapy in Alzheimer’s disease: Critical advances and future opportunities

Guo, Y., Li, S., Zeng, L.-H., & Tan, J. (2022) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.16 · Cited by 61 · see citing works

Prospects for strain-specific immunotherapy in Alzheimer’s disease and tauopathies

Bittar, A., Sengupta, U., & Kayed, R. (2018) · npj Vaccines · doi:10.1038/s41541-018-0046-8 · Cited by 50 · see citing works

The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment

Zieneldien, T., Kim, J., & Cao, C. (2022) · Geriatrics · doi:10.3390/geriatrics7020024 · Cited by 29 · see citing works

Metallomics for Alzheimer's disease treatment: Use of new generation of chelators combining metal-cation binding and transport properties

D'Acunto, C. W., Kaplánek, R., Gbelcová, H., Kejík, Z., Bříza, T., Vasina, L., Havlík, M., Ruml, T., & Král, V. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.084 · Cited by 26 · see citing works

Natural Products from Plants and Algae for Treatment of Alzheimer’s Disease: A Review

Klose, J., Griehl, C., Roßner, S., & Schilling, S. (2022) · Biomolecules · doi:10.3390/biom12050694 · Cited by 23 · see citing works

Dual Drug Repurposing: The Example of Saracatinib

Ramos, R., & Vale, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084565 · Cited by 24 · see citing works

Antioxidant and Cholinesterase Inhibitory Activities of Ethyl Acetate Extract of Terminalia chebula: Cell-Free in Vitro and in Silico Studies

Natarajan, S., Govindaraju, A., Rajmohamed, M., Palanisamy, P., & Abdulkader, A. (2017) · Pharmacognosy Magazine · doi:10.4103/pm.pm_57_17 · Cited by 20 · see citing works

DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION

Mustafa, N. H., Kelesbayev, D., & Alibekova, Z. D. (2018) · The Journal of Economic Research & Business Administration · doi:10.26577/be-2018-2-2141

Susquehanna Chorale Spring Concert "Roots and Wings"

Hawkins, D. (2017)

Genentech taps Affimed’s antibodies

Cross, R. (2018) · C&EN Global Enterprise · doi:10.1021/cen-09635-buscon15

KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK

Sari, D. (2023) · Jurnal Komplikasi Anestesi · doi:10.22146/jka.v5i1.7322

Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria

Dib, A., Puig, L. B., Salvadori, D., et al. (1988) · Arquivos Brasileiros de Cardiologia